linjc16/ctgov huggingface dataset:
Comparison of the Needle Tip Location by the Position of the Operator During Ultrasound Guided LIJV Catheterization.

Study Overview
=================
Brief Summary
-----------------
When the left internal jugular vein catheterization under short-axis ultrasound guided, an operator should be stand around the lying patient's head. The investigators are going to evaluate to effects of the operator's location.

Detailed Description
-----------------
When placing the central line catheter in the left internal jugular vein under short-axis ultrasound guided, an operator should be stand around the lying patient's head. The investigators are going to evaluate to effects of the operator's location. (Above the midline of patient's head versus above the left extended axillary line)

Official Title
-----------------
Comparison of the Needle Tip Location According to the Position of the Operator During Short Axis Ultrasound Guided Central Venous Catheterization in the Left Internal Jugular Vein

Conditions
-----------------
Catheterization, Central Venous

Intervention / Treatment
-----------------
* Other: Position change
* Other: Conventional position


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Central venous catheterization required on lt. IJV Exclusion Criteria: History of cervical spine surgery Abnormal structure of cervical spine, carotid artery or jugular vein Disease of carotid artery Immobilization due to cervical spine fracture or other diseases.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Extended axillary midline<br>Operator stands at the bedside on extended midline of the patient's lt. axilla during lt. internal jugular vein catheterization | Other: Position change<br>* Different position during central line catheterization<br>|
| Active Comparator: Extended head midline<br>Operator stands at the bedside on extended midline of the patient's head during lt. internal jugular vein catheterization. | Other: Conventional position<br>* Conventional position during central line catheterization<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distance from needle tip to center of IJV | The distance that the needle tip is placed from the center of the jugular vein when the needle is fixed after the vascular puncture | intraoperative |
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the safety and effectiveness of an investigational therapy for treating patients with open-angle glaucoma or ocular hypertension.

Official Title
-----------------
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Conditions
-----------------
Open-angle Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution
* Other: Timolol Vehicle
* Drug: Latanoprost 0.005% Ophthalmic Solution (XALATAN)
* Drug: Timolol Maleate Ophthalmic Solution 0.5%


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years or older. Diagnosis of open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension. Mean IOP in each eye less than 18 mmHg at the screening visit. Other protocol-defined inclusion criteria may apply. Exclusion Criteria: Pregnant. History of chronic or recurrent severe inflammatory eye disease. Ocular trauma within the past six months in either eye. Other protocol-defined exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Travoprost 0.004%/Timolol 0.5%<br>Travoprost 0.004%/Timolol 0.5% in both eyes each morning at 8 a.m. and Timolol vehicle in both eyes each evening at 8 p.m. for 3 months | Drug: Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution<br>* Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension<br>Other: Timolol Vehicle<br>* Placebo<br>|
| Active Comparator: Xalatan + Timolol 0.5%<br>Timolol 0.5% in both eyes each morning at 8 a.m. and Xalatan in both eyes each evening at 8 p.m. for 3 months | Drug: Latanoprost 0.005% Ophthalmic Solution (XALATAN)<br>* Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension<br>* Other names: XALATAN;Drug: Timolol Maleate Ophthalmic Solution 0.5%<br>* Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean intraocular pressure (IOP) change at 3 months from baseline |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Open-angle, glaucoma, ocular, hypertension
Genetic and Nutritional Causes of Heart Birth Defects

Study Overview
=================
Brief Summary
-----------------
Each year in the United States, thousands of babies are born with heart defects. Women who take folic acid during pregnancy have a lower risk of giving birth to infants with heart defects, but the reason for this remains unknown. This study will examine the relationship between genes, nutrition, and the occurrence of heart defects in infants.

Detailed Description
-----------------
Congenital heart defects are the most common type of birth defect; each year, more than 30,000 babies in the United States are born with this kind of abnormality. Conotruncal heart defects, considered to be a very serious type of defect, involve a structural abnormality in the chambers of the heart or blood vessels that lead to and from the heart. Infants born with conotruncal defects must undergo complex open heart surgery, and there is a high fatality rate. Folic acid supplementation during pregnancy has been shown to reduce the risk of conotruncal defects. However, some women who take folic acid during pregnancy still give birth to infants with conotruncal defects. Specific genes may influence the way individuals metabolize folic acid, and variations in these genes may make some infants more prone to developing heart defects. This study will examine the relationship between genes, maternal nutritional intake, and conotruncal heart defects. The results from this study may help to determine genetic and nutritional causes of congenital heart defects. This study will use previously collected data on 550 infants born with conotruncal defects and 1060 infants born without heart defects. There will be no study visits specifically for this study. Infant DNA will be analyzed for genes that may play a role in folate metabolic pathways. Blood previously collected from the mothers during pregnancy will be analyzed for differences in nutrient intake. Specifically, levels of folic acid, choline, vitamin B12, and methionine will be examined.

Official Title
-----------------
Gene and Nutrient Etiologies of Human Heart Defects

Conditions
-----------------
Heart Defects, Congenital

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Conotruncal heart defect Exclusion Criteria: If part of control group, must not have heart defect

Ages Eligible for Study
-----------------
Maximum Age: 12 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Congenital Heart Defects
Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to learn if changing from Tacrolimus to Everolimus will improve cognitive function by having less effect on brain blood flow.

Official Title
-----------------
Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors to Everolimus

Conditions
-----------------
End Stage Renal Disease

Intervention / Treatment
-----------------
* Drug: Tacrolimus
* Drug: Everolimus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: English speaking able to sign informed consent able to arrange transportation to and from study site without acute stroke, concussion or traumatic brain injury without acute medical issues at the time of participation At least 12 weeks post Kidney transplant surgery Exclusion Criteria: are claustrophobic or have other contra-indication for magnetic resonance imaging (MRI) have hearing or visual impairment are unable to read, write, speak or understand English have uncontrolled psychosis or seizure disorder or are currently using antipsychotics or anti-epileptics taking Envarsus at the time of recruitment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Conversion Group<br>Kidney transplant recipients at the University of Kansas Medical Center (KUMC) who are currently on tacrolimus (CNI), and will be undergoing conversion to Everolimus + low dose CNI. Potential participants will be asked to participate in the study after the decision to convert CNI to Everolimus + low dose CNI has been made. | Drug: Tacrolimus<br>* The patient's physician will prescribe drug according to standard practice.<br>* Other names: Prograf;Drug: Everolimus<br>* The patient's physician will prescribe drug according to standard practice.<br>|
| Control Group<br>Kidney transplant recipients at KUMC on tacrolimus (CNI). These will be patients not planning to undergo any change in immunosuppression. | Drug: Tacrolimus<br>* The patient's physician will prescribe drug according to standard practice.<br>* Other names: Prograf;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in cognitive function |  | Change from Baseline to Week 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in cerebral blood flow |  | Change from Baseline to Week 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Kidney transplant, Cognitive function
Symbicort in Asthmatic Children - SEEDLING

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare Symbicort with budesonide alone and formoterol alone in the treatment of asthma in children aged 6 to 11 years

Official Title
-----------------
A 12 Week Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort TM (40/4.5 Mcg) Versus Its Mono-Products (Budesonide and Formoterol) in Asthmatic Children Aged Six to Eleven Years - SEEDLING 40/4.5

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: budesonide/formoterol
* Drug: budesonide
* Drug: formoterol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Baseline lung function tests results as determined by the protocol Required and received treatment with inhaled corticosteroids within the timeframe and doses specified in the protocol Exclusion Criteria: Has required treatment with non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers Has been hospitalised or required emergency treatment for asthma-related condition within previous 6 months Has had cancer within previous 5 years or has a significant disease, as judged by investigator, that may put the patient at risk in this study

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: budesonide/formoterol<br> <br> * Other names: Symbicort;|
| Active Comparator: 2<br> | Drug: budesonide<br> <br> |
| Active Comparator: 3<br> | Drug: formoterol<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morning PEF |  | Daily | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung function, asthma symptoms, use of rescue medication, adverse events and other safety assessments |  | Throughout the treatment period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Symbicort, budesonide/formoterol, budesonide, formoterol, children
Packing of Perianal Abscess Cavities Trial: A Randomised Multicentre Trial Comparing Packing With Non-packing of the Abscess Cavity

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare the effect of packing and non-packing on the healing rate of perianal abscess cavities. Secondary objectives are to assess quality of life, cost effectiveness and rate of abscess recurrence and fistula-in-ano formation. If there is no difference in time to healing and non-packing is shown to be safe, acceptable to the patient and cost effective, this approach may become more widely accepted.

Official Title
-----------------
Packing of Perianal Abscess Cavities (PPAC) Trial: A Randomised Multicentre Trial Comparing Packing With Non-packing of the Abscess Cavity

Conditions
-----------------
Perianal Abscess

Intervention / Treatment
-----------------
* Other: Packing of abscess cavity
* Other: External dressing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of acute primary perianal abscess Have undergone surgical incision and drainage as an emergency Exclusion Criteria: The abscess is the sequelae of concurrent disease or trauma Fourniers gangrene is suspected Unable to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Non-packing of abscess cavity<br> | Other: External dressing<br>* Application of external dressing whilst abscess cavity heals<br>|
| Other: Packing of abscess cavity<br>Current practice | Other: Packing of abscess cavity<br> <br> Other: External dressing<br>* Application of external dressing whilst abscess cavity heals<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to wound healing in days, defined as complete epithelialisation of the abscess cavity. | time to healing will be assessed in days | 1 day to 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life scores as determined by the Euro QoL EQ-5D-3L | Quality of life scores as determined by the Euro QoL EQ-5D-3L will be measured at 10-14 days following incision and drainage of abscess | 10 to 14 days |
Tranexamic Acid in Hip Fracture Surgery

Study Overview
=================
Brief Summary
-----------------
To determine if TXA utilization is effective at reducing transfusion rates in elderly patients undergoing surgery for treatment of a hip fractures.

Official Title
-----------------
Effectiveness of Tranexamic Acid (TXA) in Reducing Blood Loss in Hip Fracture Surgery

Conditions
-----------------
Hip Fracture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute, isolated, unilateral femoral neck, intertrochanteric, and per trochanteric hip fractures confirmed by anteroposterior/lateral hip radiographs, computed tomography, or magnetic resonance imaging. Age 65 and older Low energy mechanism of injury Hip fracture fixation performed within 48 hours English speaking Anticipated medical optimization for operative fixation No other major trauma Exclusion Criteria: Retained hardware around the affected hip Infection around the affected hip Transfer patients with a length of stay > 24 hours at the transferring hospital Diagnosis of deficient natural anticoagulation Known congenital thrombophilia (Deficiency of Protein C, S, Antithrombin) Known allergy to TXA Patients undergoing percutaneous pinning of the hip fracture

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Tranexamic Acid<br>Patients that receive 2 gm TXA during surgery | |
| No Tranexamic Acid<br>Patients that receive no TXA during surgery | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood Transfusion Rate | Blood transfusion rates during the patients hospital stay will be assessed. | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospital Length of stay | The patients length of stay in the hospital will be determined. | 6 weeks | 
| Post operative complications | Post operative complications will be assessed through the 6 weeks. | 6 weeks | 
| Hospitalization costs | Economic evaluation for inpatient and re-admission will be assessed. | 6 weeks |
Effects of Intrathecal Local Anesthetics on Left Ventricular Global Longitudinal Strain

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to assess the effects of intrathecal local anesthetics on left ventricular global longitudinal strain (LVGLS) using transthoracic echocardiography (TTE).

Official Title
-----------------
Effects of Intrathecal Local Anesthetics on Left Ventricular Global Longitudinal Strain

Conditions
-----------------
Left Ventricular Dysfunction, Spinal Anesthetics Causing Adverse Effects in Therapeutic Use, Global Cardiac Wall Motion Dysfunction

Intervention / Treatment
-----------------
* Drug: Intrathecal local anesthesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients undergoing elective knee and hip replacements under spinal anesthesia Exclusion Criteria: Patients who do not wish to consent Patients with contraindications to TTE Patients with reduced left ventricular systolic function as defined by LV ejection fraction < 50% on pre-operative echocardiography Patients with body mass index greater than 40 Non-English-speaking subjects Cognitively impaired adults

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Intrathecal local anesthesia|Administration of local anesthetic into intrathecal space to achieve surgical anesthesia|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Left Ventricular Global Longitudinal Strain |  | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Left Ventricular Ejection Fraction |  | 5 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Strain